The use and abuse of surrogate endpoints in clinical research in transfusion medicine

Transfusion

Volumn 48, Issue 8, 2008, Pages 1547-1549

  Arnold, Donald M ^a   Lim, Wendy ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

BIOASSAY; BLOOD TRANSFUSION; CLINICAL RESEARCH; CRITICALLY ILL PATIENT; DISEASE MARKER; DISEASE SEVERITY; HEALTH HAZARD; HUMAN; LABORATORY TEST; MORTALITY; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; THALASSEMIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 48249107115     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01774.x     Document Type: Review

References (17)

1. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001 22 : 485 502.
2. Wheatley K, Clayton D. Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. Control Clin Trials 2003 24 : 66 70.
3. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989 8 : 431 40.
4. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005 105 : 1114 8.
5. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In : Nimmo W, Tucker G, editors. Clinical measurement in drug evaluation. New York : J. Wiley 1995. p. 322.
6. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996 125 : 605 13.
7. Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 2007 47 : 464 70.
8. Pilz G, Kreuzer E, Kaab S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994 105 : 76 82.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985 13 : 818 29.
10. Werdan K, Pilz G, Mueller-Werdan U, Enriquez MM, Schmitt DV, Mohr FW, Neeser G, Schondube F, Schafers HJ, Haverich A, Fraunberger P, Kreuzer E, Thijs LG. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome - the ESSICS study. Crit Care Med 2008 36 : 716 23.
11. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 62.
12. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 : 3738 44.
13. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006 107 : 3436 41.
14. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006 107 : 3733 7.
15. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997 42 : 699 704.
16. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998 339 : 5 11.
17. Heddle N, Arnold D, Boye D, Webert K, Resz I, Dumont L. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion DOI: 10.1111/j.1537-2995.2008.01731.x